NCT06463093

Brief Summary

The aim of the research is to analyze whether 18F-FDG PET helps in the diagnosis and therefore in the management of the patient.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
20

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Nov 2024

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

November 27, 2023

Completed
7 months until next milestone

First Posted

Study publicly available on registry

June 17, 2024

Completed
6 months until next milestone

Study Start

First participant enrolled

November 30, 2024

Completed
2 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 30, 2025

Completed
5 months until next milestone

Study Completion

Last participant's last visit for all outcomes

July 2, 2025

Completed
Last Updated

June 25, 2026

Status Verified

June 1, 2026

Enrollment Period

2 months

First QC Date

November 27, 2023

Last Update Submit

June 23, 2026

Conditions

Neurocognitive Disorders

Outcome Measures

Primary Outcomes (1)

  • Neuro cognitive disorders and disorders of neurodegenerative origin in psychiatric population

    Change of the diagnosis before the PET and after the PET

    one day

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients treated for psychiatric reasons with neurocognitive disorders in the clinic, having consulted or being hospitalized at the psychotherapeutic center of Nancy between 01/01/2021 to 01/01/2024 and having undergone a flurodeoxyglucose positron emission tomography marked with fluorine 18 carried out in the course of care

You may qualify if:

  • Adult patients with cognitive impairment
  • Positron emission tomography with flurodeoxyglucose labeled with fluorine 18 carried out in the course of care

You may not qualify if:

  • Patients objecting to the collection of their data

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Nancy's hospital

Vandœuvre-lès-Nancy, 54511, France

Location

MeSH Terms

Conditions

Neurocognitive Disorders

Condition Hierarchy (Ancestors)

Mental Disorders

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

November 27, 2023

First Posted

June 17, 2024

Study Start

November 30, 2024

Primary Completion

January 30, 2025

Study Completion

July 2, 2025

Last Updated

June 25, 2026

Record last verified: 2026-06

Locations

FR(1)